Establishment Labs’ (ESTA) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Establishment Labs (NASDAQ:ESTA) in a research note released on Wednesday morning,Benzinga reports. The firm currently has a $88.00 target price on the stock.

Several other research firms have also recently weighed in on ESTA. Needham & Company LLC upped their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Canaccord Genuity Group upped their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Mizuho upped their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.86.

Establishment Labs Trading Up 2.3%

Shares of ESTA opened at $70.23 on Wednesday. The business’s 50-day moving average price is $65.53 and its 200-day moving average price is $65.71. Establishment Labs has a twelve month low of $31.04 and a twelve month high of $83.31. The stock has a market cap of $2.06 billion, a PE ratio of -40.36 and a beta of 1.12. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. During the same period in the prior year, the business posted ($1.19) earnings per share. The company’s revenue was up 45.2% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs will post -0.86 EPS for the current fiscal year.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 2,180 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $66.26, for a total value of $144,446.80. Following the completion of the sale, the director owned 1,107,504 shares of the company’s stock, valued at $73,383,215.04. This represents a 0.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 150,000 shares of company stock valued at $9,629,263 over the last ninety days. 9.99% of the stock is owned by corporate insiders.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new stake in Establishment Labs in the fourth quarter worth approximately $47,000. Quarry LP purchased a new stake in Establishment Labs in the third quarter worth approximately $34,000. State of Wyoming purchased a new stake in Establishment Labs in the third quarter worth approximately $71,000. MV Capital Management Inc. purchased a new stake in Establishment Labs in the fourth quarter worth approximately $146,000. Finally, Osaic Holdings Inc. boosted its stake in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.